Loading...

Pope Whitney

TitleProfessor In-Residence
InstitutionUniversity of California Los Angeles
DepartmentRadiology
Address757 Westwood Plaza
1621E
Los Angeles CA 90095
Phone(310) 267-9783
vCardDownload vCard

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. Chakhoyan A, Woodworth DC, Harris RJ, Lai A, Nghiemphu PL, Liau LM, Pope WB, Cloughesy TF, Ellingson BM. Mono-exponential, diffusion kurtosis and stretched exponential diffusion MR imaging response to chemoradiation in newly diagnosed glioblastoma. J Neurooncol. 2018 May 31. PMID: 29855771.
      View in: PubMed
    2. Young JR, Qiao J, Orosz I, Salamon N, Franke MA, Kim HJ, Pope WB. Gadolinium deposition within the paediatric brain: no increased intrinsic T1-weighted signal intensity within the dentate nucleus following the administration of a minimum of four doses of the macrocyclic agent gadobutrol. Eur Radiol. 2018 May 09. PMID: 29744642.
      View in: PubMed
    3. Pope WB, Brandal G. Conventional and advanced magnetic resonance imaging in patients with high grade glioma. Q J Nucl Med Mol Imaging. 2018 Apr 26. PMID: 29696946.
      View in: PubMed
    4. Patel CB, Fazzari E, Chakhoyan A, Yao J, Raymond C, Nguyen H, Manoukian J, Nguyen N, Pope W, Cloughesy TF, Nghiemphu PL, Czernin J, Lai A, Ellingson BM. 18F-FDOPA PET and MRI characteristics correlate with degree of malignancy and predict survival in treatment-naïve gliomas: a cross-sectional study. J Neurooncol. 2018 Apr 20. PMID: 29679199.
      View in: PubMed
    5. Ellingson BM, Abrey LE, Garcia J, Chinot O, Wick W, Saran F, Nishikawa R, Henriksson R, Mason WP, Harris RJ, Leu K, Woodworth DC, Mehta A, Raymond C, Chakhoyan A, Pope WB, Cloughesy TF. Post-chemoradiation volumetric response predicts survival in newly diagnosed glioblastoma treated with radiation, temozolomide and bevacizumab or placebo. Neuro Oncol. 2018 Apr 20. PMID: 29897562.
      View in: PubMed
    6. Harris RJ, Yao J, Chakhoyan A, Raymond C, Leu K, Liau LM, Nghiemphu PL, Lai A, Salamon N, Pope WB, Cloughesy TF, Ellingson BM. Simultaneous pH-sensitive and oxygen-sensitive MRI of human gliomas at 3 T using multi-echo amine proton chemical exchange saturation transfer spin-and-gradient echo echo-planar imaging (CEST-SAGE-EPI). Magn Reson Med. 2018 Apr 06. PMID: 29626359.
      View in: PubMed
    7. Ellingson BM, Abrey LE, Nelson SJ, Kaufmann TJ, Garcia J, Chinot O, Saran F, Nishikawa R, Henriksson R, Mason WP, Wick W, Butowski N, Ligon KL, Gerstner ER, Colman H, de Groot J, Chang S, Mellinghoff I, Young RJ, Alexander BM, Colen R, Taylor JW, Arrillaga-Romany I, Mehta A, Huang RY, Pope WB, Reardon D, Batchelor T, Prados M, Galanis E, Wen PY, Cloughesy TF. Validation of post-operative residual contrast enhancing tumor volume as an independent prognostic factor for overall survival in newly diagnosed glioblastoma. Neuro Oncol. 2018 Apr 05. PMID: 29660006.
      View in: PubMed
    8. Kong XT, Nguyen NT, Choi YJ, Zhang G, Nguyen HN, Filka E, Green S, Yong WH, Liau LM, Green RM, Kaprealian T, Pope WB, Nghiemphu PL, Cloughesy T, Lassman A, Lai A. Phase 2 Study of Bortezomib Combined With Temozolomide and Regional Radiation Therapy for Upfront Treatment of Patients With Newly Diagnosed Glioblastoma Multiforme: Safety and Efficacy Assessment. Int J Radiat Oncol Biol Phys. 2018 Apr 01; 100(5):1195-1203. PMID: 29722661.
      View in: PubMed
    9. Pope WB. Brain metastases: neuroimaging. Handb Clin Neurol. 2018; 149:89-112. PMID: 29307364.
      View in: PubMed
    10. Qiao XJ, Kim HG, Wang DJJ, Salamon N, Linetsky M, Sepahdari A, Ellingson BM, Pope WB. Application of arterial spin labeling perfusion MRI to differentiate benign from malignant intracranial meningiomas. Eur J Radiol. 2017 Dec; 97:31-36. PMID: 29153364.
      View in: PubMed
    11. Ellingson BM, Gerstner ER, Smits M, Huang RY, Colen R, Abrey LE, Aftab DT, Schwab GM, Hessel C, Harris RJ, Chakhoyan A, Gahrmann R, Pope WB, Leu K, Raymond C, Woodworth DC, de Groot J, Wen PY, Batchelor TT, van den Bent MJ, Cloughesy TF. Diffusion MRI Phenotypes Predict Overall Survival Benefit from Anti-VEGF Monotherapy in Recurrent Glioblastoma: Converging Evidence from Phase II Trials. Clin Cancer Res. 2017 Oct 01; 23(19):5745-5756. PMID: 28655794.
      View in: PubMed
    12. Boxerman JL, Ellingson BM, Jeyapalan S, Elinzano H, Harris RJ, Rogg JM, Pope WB, Safran H. Longitudinal DSC-MRI for Distinguishing Tumor Recurrence From Pseudoprogression in Patients With a High-grade Glioma. Am J Clin Oncol. 2017 Jun; 40(3):228-234. PMID: 25436828.
      View in: PubMed
    13. Leu K, Ott GA, Lai A, Nghiemphu PL, Pope WB, Yong WH, Liau LM, Cloughesy TF, Ellingson BM. Perfusion and diffusion MRI signatures in histologic and genetic subtypes of WHO grade II-III diffuse gliomas. J Neurooncol. 2017 Aug; 134(1):177-188. PMID: 28547590.
      View in: PubMed
    14. Ellingson BM, Chung C, Pope WB, Boxerman JL, Kaufmann TJ. Pseudoprogression, radionecrosis, inflammation or true tumor progression? challenges associated with glioblastoma response assessment in an evolving therapeutic landscape. J Neurooncol. 2017 Sep; 134(3):495-504. PMID: 28382534.
      View in: PubMed
    15. de Oliveira EA, Lazovic J, Guo L, Soto H, Faintuch BL, Akhtari M, Pope W. Evaluation of Magnetonanoparticles Conjugated with New Angiogenesis Peptides in Intracranial Glioma Tumors by MRI. Appl Biochem Biotechnol. 2017 Sep; 183(1):265-279. PMID: 28281182.
      View in: PubMed
    16. Galldiks N, Law I, Pope WB, Arbizu J, Langen KJ. The use of amino acid PET and conventional MRI for monitoring of brain tumor therapy. Neuroimage Clin. 2017; 13:386-394. PMID: 28116231.
      View in: PubMed
    17. Abdaljaleel M, Mazumder R, Patel CB, Im K, Pope W, Liau LM, Vinters HV, Yong WH. Multiple calcifying pseudoneoplasms of the neuraxis (MCAPNON): Distinct entity, CAPNON variant, or old neurocysticercosis? Neuropathology. 2017 Jun; 37(3):233-240. PMID: 27862397.
      View in: PubMed
    18. Harris RJ, Cloughesy TF, Liau LM, Nghiemphu PL, Lai A, Pope WB, Ellingson BM. Simulation, phantom validation, and clinical evaluation of fast pH-weighted molecular imaging using amine chemical exchange saturation transfer echo planar imaging (CEST-EPI) in glioma at 3?T. NMR Biomed. 2016 11; 29(11):1563-1576. PMID: 27717216.
      View in: PubMed
    19. Boxerman JL, Shiroishi MS, Ellingson BM, Pope WB. Dynamic Susceptibility Contrast MR Imaging in Glioma: Review of Current Clinical Practice. Magn Reson Imaging Clin N Am. 2016 Nov; 24(4):649-670. PMID: 27742108.
      View in: PubMed
    20. Ellingson BM, Harris RJ, Woodworth DC, Leu K, Zaw O, Mason WP, Sahebjam S, Abrey LE, Aftab DT, Schwab GM, Hessel C, Lai A, Nghiemphu PL, Pope WB, Wen PY, Cloughesy TF. Baseline pretreatment contrast enhancing tumor volume including central necrosis is a prognostic factor in recurrent glioblastoma: evidence from single and multicenter trials. Neuro Oncol. 2017 01; 19(1):89-98. PMID: 27580889.
      View in: PubMed
    21. Hathout L, Ellingson B, Pope W. Modeling the efficacy of the extent of surgical resection in the setting of radiation therapy for glioblastoma. Cancer Sci. 2016 Aug; 107(8):1110-6. PMID: 27240229; PMCID: PMC4982585.
    22. Albert NL, Weller M, Suchorska B, Galldiks N, Soffietti R, Kim MM, la Fougère C, Pope W, Law I, Arbizu J, Chamberlain MC, Vogelbaum M, Ellingson BM, Tonn JC. Response Assessment in Neuro-Oncology working group and European Association for Neuro-Oncology recommendations for the clinical use of PET imaging in gliomas. Neuro Oncol. 2016 09; 18(9):1199-208. PMID: 27106405; PMCID: PMC4999003 [Available on 09/01/17].
    23. Ellingson BM, Nguyen HN, Lai A, Nechifor RE, Zaw O, Pope WB, Yong WH, Nghiemphu PL, Liau LM, Cloughesy TF. Contrast-enhancing tumor growth dynamics of preoperative, treatment-naive human glioblastoma. Cancer. 2016 06 01; 122(11):1718-27. PMID: 26998740.
      View in: PubMed
    24. Leu K, Boxerman JL, Lai A, Nghiemphu PL, Pope WB, Cloughesy TF, Ellingson BM. Bidirectional Contrast agent leakage correction of dynamic susceptibility contrast (DSC)-MRI improves cerebral blood volume estimation and survival prediction in recurrent glioblastoma treated with bevacizumab. J Magn Reson Imaging. 2016 Nov; 44(5):1229-1237. PMID: 26971534.
      View in: PubMed
    25. Pope WB, Djoukhadar I, Jackson A. Neuroimaging. Handb Clin Neurol. 2016; 134:27-50. PMID: 26948347.
      View in: PubMed
    26. Okada H, Weller M, Huang R, Finocchiaro G, Gilbert MR, Wick W, Ellingson BM, Hashimoto N, Pollack IF, Brandes AA, Franceschi E, Herold-Mende C, Nayak L, Panigrahy A, Pope WB, Prins R, Sampson JH, Wen PY, Reardon DA. Immunotherapy response assessment in neuro-oncology: a report of the RANO working group. Lancet Oncol. 2015 Nov; 16(15):e534-e542. PMID: 26545842.
      View in: PubMed
    27. Pope WB. Evidence for rCBV as an early response marker following bevacizumab treatment. Neuro Oncol. 2015 Nov; 17(11):1539-40. PMID: 26453577; PMCID: PMC4648311 [Available on 11/01/16].
    28. Banerjee P, Leu K, Harris RJ, Cloughesy TF, Lai A, Nghiemphu PL, Pope WB, Bookheimer SY, Ellingson BM. Association between lesion location and language function in adult glioma using voxel-based lesion-symptom mapping. Neuroimage Clin. 2015; 9:617-24. PMID: 26740915; PMCID: PMC4644251.
    29. Huang RY, Rahman R, Ballman KV, Felten SJ, Anderson SK, Ellingson BM, Nayak L, Lee EQ, Abrey LE, Galanis E, Reardon DA, Pope WB, Cloughesy TF, Wen PY. The Impact of T2/FLAIR Evaluation per RANO Criteria on Response Assessment of Recurrent Glioblastoma Patients Treated with Bevacizumab. Clin Cancer Res. 2016 Feb 01; 22(3):575-81. PMID: 26490307.
      View in: PubMed
    30. Shiroishi MS, Boxerman JL, Pope WB. Physiologic MRI for assessment of response to therapy and prognosis in glioblastoma. Neuro Oncol. 2016 Apr; 18(4):467-78. PMID: 26364321; PMCID: PMC4799679 [Available on 04/01/17].
    31. Magaki S, Chang E, Hammond RR, Yang I, Mackenzie IR, Chou BT, Choi SI, Jen JC, Pope WB, Bell DA, Vinters HV. Two cases of rheumatoid meningitis. Neuropathology. 2016 Feb; 36(1):93-102. PMID: 26350538.
      View in: PubMed
    32. Chang W, Pope WB, Harris RJ, Hardy AJ, Leu K, Mody RR, Nghiemphu PL, Lai A, Cloughesy TF, Ellingson BM. Diffusion MR Characteristics Following Concurrent Radiochemotherapy Predicts Progression-Free and Overall Survival in Newly Diagnosed Glioblastoma. Tomography. 2015 Sep; 1(1):37-43. PMID: 26740971.
      View in: PubMed
    33. Ellingson BM, Bendszus M, Boxerman J, Barboriak D, Erickson BJ, Smits M, Nelson SJ, Gerstner E, Alexander B, Goldmacher G, Wick W, Vogelbaum M, Weller M, Galanis E, Kalpathy-Cramer J, Shankar L, Jacobs P, Pope WB, Yang D, Chung C, Knopp MV, Cha S, van den Bent MJ, Chang S, Yung WK, Cloughesy TF, Wen PY, Gilbert MR. Consensus recommendations for a standardized Brain Tumor Imaging Protocol in clinical trials. Neuro Oncol. 2015 Sep; 17(9):1188-98. PMID: 26250565; PMCID: PMC4588759.
    34. Galldiks N, Langen KJ, Pope WB. From the clinician's point of view - What is the status quo of positron emission tomography in patients with brain tumors? Neuro Oncol. 2015 Nov; 17(11):1434-44. PMID: 26130743; PMCID: PMC4648307 [Available on 11/01/16].
    35. Harris RJ, Cloughesy TF, Liau LM, Prins RM, Antonios JP, Li D, Yong WH, Pope WB, Lai A, Nghiemphu PL, Ellingson BM. pH-weighted molecular imaging of gliomas using amine chemical exchange saturation transfer MRI. Neuro Oncol. 2015 Nov; 17(11):1514-24. PMID: 26113557; PMCID: PMC4648305 [Available on 11/01/16].
    36. Hathout L, Pope WB, Lai A, Nghiemphu PL, Cloughesy TF, Ellingson BM. Radial expansion rates and tumor growth kinetics predict malignant transformation in contrast-enhancing low-grade diffuse astrocytoma. CNS Oncol. 2015; 4(4):247-56. PMID: 26095141; PMCID: PMC4538925.
    37. Karavaeva E, Harris RJ, Leu K, Shabihkhani M, Yong WH, Pope WB, Lai A, Nghiemphu PL, Liau LM, Chen W, Czernin J, Cloughesy TF, Ellingson BM. Relationship Between [18F]FDOPA PET Uptake, Apparent Diffusion Coefficient (ADC), and Proliferation Rate in Recurrent Malignant Gliomas. Mol Imaging Biol. 2015 Jun; 17(3):434-42. PMID: 25465392.
      View in: PubMed
    38. Hathout L, Ellingson BM, Cloughesy TF, Pope WB. Patient-specific characterization of the invasiveness and proliferation of low-grade gliomas using serial MR imaging and a mathematical model of tumor growth. Oncol Rep. 2015 Jun; 33(6):2883-8. PMID: 25962999.
      View in: PubMed
    39. Pope WB. Predictive imaging marker of bevacizumab efficacy: perfusion MRI. Neuro Oncol. 2015 Aug; 17(8):1046-7. PMID: 25910842; PMCID: PMC4490878.
    40. Ellingson BM, Lai A, Nguyen HN, Nghiemphu PL, Pope WB, Cloughesy TF. Quantification of Nonenhancing Tumor Burden in Gliomas Using Effective T2 Maps Derived from Dual-Echo Turbo Spin-Echo MRI. Clin Cancer Res. 2015 Oct 01; 21(19):4373-83. PMID: 25901082; PMCID: PMC4592379 [Available on 10/01/16].
    41. Harris RJ, Cloughesy TF, Hardy AJ, Liau LM, Pope WB, Nghiemphu PL, Lai A, Ellingson BM. MRI perfusion measurements calculated using advanced deconvolution techniques predict survival in recurrent glioblastoma treated with bevacizumab. J Neurooncol. 2015 May; 122(3):497-505. PMID: 25773062.
      View in: PubMed
    42. Pope WB. Genomics of brain tumor imaging. Neuroimaging Clin N Am. 2015 Feb; 25(1):105-19. PMID: 25476516.
      View in: PubMed
    43. Gilbert MR, Armstrong TS, Pope WB, van den Bent MJ, Wen PY. Facing the future of brain tumor clinical research. Clin Cancer Res. 2014 Nov 15; 20(22):5591-600. PMID: 25398842.
      View in: PubMed
    44. Leu K, Enzmann DR, Woodworth DC, Harris RJ, Tran AN, Lai A, Nghiemphu PL, Pope WB, Cloughesy TF, Ellingson BM. Hypervascular tumor volume estimated by comparison to a large-scale cerebral blood volume radiographic atlas predicts survival in recurrent glioblastoma treated with bevacizumab. Cancer Imaging. 2014 Nov 14; 14:31. PMID: 25608485; PMCID: PMC4331836.
    45. Hathout L, Ellingson BM, Cloughesy T, Pope WB. A novel bicompartmental mathematical model of glioblastoma multiforme. Int J Oncol. 2015 Feb; 46(2):825-32. PMID: 25384756.
      View in: PubMed
    46. Ellingson BM, Bendszus M, Sorensen AG, Pope WB. Emerging techniques and technologies in brain tumor imaging. Neuro Oncol. 2014 Oct; 16 Suppl 7:vii12-23. PMID: 25313234; PMCID: PMC4195527.
    47. Wen PY, Cloughesy TF, Ellingson BM, Reardon DA, Fine HA, Abrey L, Ballman K, Bendszuz M, Buckner J, Chang SM, Prados MD, Pope WB, Gregory Sorensen A, van den Bent M, Yung WK. Report of the Jumpstarting Brain Tumor Drug Development Coalition and FDA clinical trials neuroimaging endpoint workshop (January 30, 2014, Bethesda MD). Neuro Oncol. 2014 Oct; 16 Suppl 7:vii36-47. PMID: 25313237; PMCID: PMC4195530.
    48. Lazovic J, Guo L, Nakashima J, Mirsadraei L, Yong W, Kim HJ, Ellingson B, Wu H, Pope WB. Nitroxoline induces apoptosis and slows glioma growth in vivo. Neuro Oncol. 2015 Jan; 17(1):53-62. PMID: 25074541; PMCID: PMC4483047.
    49. Pope WB. Intraoperative mass spectrometry of tumor metabolites. Proc Natl Acad Sci U S A. 2014 Jul 29; 111(30):10906-7. PMID: 25028494; PMCID: PMC4121782.
    50. Schwarzenberg J, Czernin J, Cloughesy TF, Ellingson BM, Pope WB, Grogan T, Elashoff D, Geist C, Silverman DH, Phelps ME, Chen W. Treatment response evaluation using 18F-FDOPA PET in patients with recurrent malignant glioma on bevacizumab therapy. Clin Cancer Res. 2014 Jul 01; 20(13):3550-9. PMID: 24687922; PMCID: PMC4079729.
    51. Piccioni DE, Selfridge J, Mody RR, Chowdhury R, Li S, Lalezari S, Wawrzynski J, Quan J, Zurayk M, Chou AP, Sanchez DE, Liau LM, Ellingson BM, Pope WB, Nghiemphu PL, Green RM, Wang HJ, Yong WH, Elashoff R, Cloughesy TF, Lai A. Deferred use of bevacizumab for recurrent glioblastoma is not associated with diminished efficacy. Neuro Oncol. 2014 Jun; 16(6):815-22. PMID: 24627236; PMCID: PMC4022228.
    52. Avliyakulov NK, Rajavel KS, Le KM, Guo L, Mirsadraei L, Yong WH, Liau LM, Li S, Lai A, Nghiemphu PL, Cloughesy TF, Linetsky M, Haykinson MJ, Pope WB. C-terminally truncated form of aB-crystallin is associated with IDH1 R132H mutation in anaplastic astrocytoma. J Neurooncol. 2014 Mar; 117(1):53-65. PMID: 24473683.
      View in: PubMed
    53. Zaw TM, Pope WB, Cloughesy TF, Lai A, Nghiemphu PL, Ellingson BM. Short-interval estimation of proliferation rate using serial diffusion MRI predicts progression-free survival in newly diagnosed glioblastoma treated with radiochemotherapy. J Neurooncol. 2014 Feb; 116(3):601-8. PMID: 24395348; PMCID: PMC3955987.
    54. Harris RJ, Bookheimer SY, Cloughesy TF, Kim HJ, Pope WB, Lai A, Nghiemphu PL, Liau LM, Ellingson BM. Altered functional connectivity of the default mode network in diffuse gliomas measured with pseudo-resting state fMRI. J Neurooncol. 2014 Jan; 116(2):373-9. PMID: 24234804.
      View in: PubMed
    55. Kallen ME, Boon-Unge K, Yong WH, Pope WB, Frazee JG, Vinters HV. Isolated choroid plexus granulomas: initial presentation of neurosarcoidosis? Can J Neurol Sci. 2014 Jan; 41(1):112-4. PMID: 24384351.
      View in: PubMed
    56. Woodworth DC, Pope WB, Liau LM, Kim HJ, Lai A, Nghiemphu PL, Cloughesy TF, Ellingson BM. Nonlinear distortion correction of diffusion MR images improves quantitative DTI measurements in glioblastoma. J Neurooncol. 2014 Feb; 116(3):551-8. PMID: 24318915; PMCID: PMC3918907.
    57. Tran AN, Lai A, Li S, Pope WB, Teixeira S, Harris RJ, Woodworth DC, Nghiemphu PL, Cloughesy TF, Ellingson BM. Increased sensitivity to radiochemotherapy in IDH1 mutant glioblastoma as demonstrated by serial quantitative MR volumetry. Neuro Oncol. 2014 Mar; 16(3):414-20. PMID: 24305712; PMCID: PMC3922511.
    58. Ellingson BM, Kim HJ, Woodworth DC, Pope WB, Cloughesy JN, Harris RJ, Lai A, Nghiemphu PL, Cloughesy TF. Recurrent glioblastoma treated with bevacizumab: contrast-enhanced T1-weighted subtraction maps improve tumor delineation and aid prediction of survival in a multicenter clinical trial. Radiology. 2014 Apr; 271(1):200-10. PMID: 24475840; PMCID: PMC4263651.
    59. Huo J, Okada K, van Rikxoort EM, Kim HJ, Alger JR, Pope WB, Goldin JG, Brown MS. Ensemble segmentation for GBM brain tumors on MR images using confidence-based averaging. Med Phys. 2013 Sep; 40(9):093502. PMID: 24007185.
      View in: PubMed
    60. Wang DJ, Alger JR, Qiao JX, Gunther M, Pope WB, Saver JL, Salamon N, Liebeskind DS. Multi-delay multi-parametric arterial spin-labeled perfusion MRI in acute ischemic stroke - Comparison with dynamic susceptibility contrast enhanced perfusion imaging. Neuroimage Clin. 2013; 3:1-7. PMID: 24159561; PMCID: PMC3791289.
    61. Akhtari M, Pope W, Mathern G, Moats R, Frew A, Mandelkern M. Functionalized magnetonanoparticles in visualization of intracranial tumors on MRI. Mol Imaging Biol. 2013 Jun; 15(3):299-306. PMID: 23184607.
      View in: PubMed
    62. Naeini KM, Pope WB, Cloughesy TF, Harris RJ, Lai A, Eskin A, Chowdhury R, Phillips HS, Nghiemphu PL, Behbahanian Y, Ellingson BM. Identifying the mesenchymal molecular subtype of glioblastoma using quantitative volumetric analysis of anatomic magnetic resonance images. Neuro Oncol. 2013 May; 15(5):626-34. PMID: 23444259; PMCID: PMC3635524.
    63. Wu W, Tanrivermis Sayit A, Vinters HV, Pope W, Mirsadraei L, Said J. Primary central nervous system histiocytic sarcoma presenting as a postradiation sarcoma: case report and literature review. Hum Pathol. 2013 Jun; 44(6):1177-83. PMID: 23356953.
      View in: PubMed
    64. Harris RJ, Cloughesy TF, Pope WB, Godinez S, Natsuaki Y, Nghiemphu PL, Meyer H, Paul D, Behbahanian Y, Lai A, Ellingson BM. Pre- and post-contrast three-dimensional double inversion-recovery MRI in human glioblastoma. J Neurooncol. 2013 Apr; 112(2):257-66. PMID: 23344788; PMCID: PMC3616610.
    65. Lalezari S, Chou AP, Tran A, Solis OE, Khanlou N, Chen W, Li S, Carrillo JA, Chowdhury R, Selfridge J, Sanchez DE, Wilson RW, Zurayk M, Lalezari J, Lou JJ, Ormiston L, Ancheta K, Hanna R, Miller P, Piccioni D, Ellingson BM, Buchanan C, Mischel PS, Nghiemphu PL, Green R, Wang HJ, Pope WB, Liau LM, Elashoff RM, Cloughesy TF, Yong WH, Lai A. Combined analysis of O6-methylguanine-DNA methyltransferase protein expression and promoter methylation provides optimized prognostication of glioblastoma outcome. Neuro Oncol. 2013 Mar; 15(3):370-81. PMID: 23328811; PMCID: PMC3578486.
    66. Leu K, Pope WB, Cloughesy TF, Lai A, Nghiemphu PL, Chen W, Liau LM, Ellingson BM. Imaging biomarkers for antiangiogenic therapy in malignant gliomas. CNS Oncol. 2013 Jan; 2(1):33-47. PMID: 24570837; PMCID: PMC3932329.
    67. Ellingson BM, Cloughesy TF, Lai A, Nghiemphu PL, Liau LM, Pope WB. Quantitative probabilistic functional diffusion mapping in newly diagnosed glioblastoma treated with radiochemotherapy. Neuro Oncol. 2013 Mar; 15(3):382-90. PMID: 23275575; PMCID: PMC3578489.
    68. Khan SN, Linetsky M, Ellingson BM, Pope WB. Magnetic Resonance Imaging of Glioma in the Era of Antiangiogenic Therapy. PET Clin. 2013 Apr; 8(2):163-82. PMID: 27157946.
      View in: PubMed
    69. Ellingson BM, Chen W, Harris RJ, Pope WB, Lai A, Nghiemphu PL, Czernin J, Phelps ME, Cloughesy TF. PET Parametric Response Mapping for Clinical Monitoring and Treatment Response Evaluation in Brain Tumors. PET Clin. 2013 Apr; 8(2):201-17. PMID: 27157948.
      View in: PubMed
    70. Lazovic J, Soto H, Piccioni D, Lou JR, Li S, Mirsadraei L, Yong W, Prins R, Liau LM, Ellingson BM, Cloughesy TF, Lai A, Pope WB. Detection of 2-hydroxyglutaric acid in vivo by proton magnetic resonance spectroscopy in U87 glioma cells overexpressing isocitrate dehydrogenase-1 mutation. Neuro Oncol. 2012 Dec; 14(12):1465-72. PMID: 23090985; PMCID: PMC3499014.
    71. Harris RJ, Cloughesy TF, Pope WB, Nghiemphu PL, Lai A, Zaw T, Czernin J, Phelps ME, Chen W, Ellingson BM. 18F-FDOPA and 18F-FLT positron emission tomography parametric response maps predict response in recurrent malignant gliomas treated with bevacizumab. Neuro Oncol. 2012 Aug; 14(8):1079-89. PMID: 22711609; PMCID: PMC3408264.
    72. White CM, Pope WB, Zaw T, Qiao J, Naeini KM, Lai A, Nghiemphu PL, Wang JJ, Cloughesy TF, Ellingson BM. Regional and voxel-wise comparisons of blood flow measurements between dynamic susceptibility contrast magnetic resonance imaging (DSC-MRI) and arterial spin labeling (ASL) in brain tumors. J Neuroimaging. 2014 Jan-Feb; 24(1):23-30. PMID: 22672084.
      View in: PubMed
    73. Pope WB, Qiao XJ, Kim HJ, Lai A, Nghiemphu P, Xue X, Ellingson BM, Schiff D, Aregawi D, Cha S, Puduvalli VK, Wu J, Yung WK, Young GS, Vredenburgh J, Barboriak D, Abrey LE, Mikkelsen T, Jain R, Paleologos NA, Rn PL, Prados M, Goldin J, Wen PY, Cloughesy T. Apparent diffusion coefficient histogram analysis stratifies progression-free and overall survival in patients with recurrent GBM treated with bevacizumab: a multi-center study. J Neurooncol. 2012 Jul; 108(3):491-8. PMID: 22426926; PMCID: PMC3997502.
    74. Wang DJ, Alger JR, Qiao JX, Hao Q, Hou S, Fiaz R, Gunther M, Pope WB, Saver JL, Salamon N, Liebeskind DS. The value of arterial spin-labeled perfusion imaging in acute ischemic stroke: comparison with dynamic susceptibility contrast-enhanced MRI. Stroke. 2012 Apr; 43(4):1018-24. PMID: 22328551; PMCID: PMC3314714.
    75. Ellingson BM, Zaw T, Cloughesy TF, Naeini KM, Lalezari S, Mong S, Lai A, Nghiemphu PL, Pope WB. Comparison between intensity normalization techniques for dynamic susceptibility contrast (DSC)-MRI estimates of cerebral blood volume (CBV) in human gliomas. J Magn Reson Imaging. 2012 Jun; 35(6):1472-7. PMID: 22281731.
      View in: PubMed
    76. Ellingson BM, Cloughesy TF, Zaw T, Lai A, Nghiemphu PL, Harris R, Lalezari S, Wagle N, Naeini KM, Carrillo J, Liau LM, Pope WB. Functional diffusion maps (fDMs) evaluated before and after radiochemotherapy predict progression-free and overall survival in newly diagnosed glioblastoma. Neuro Oncol. 2012 Mar; 14(3):333-43. PMID: 22270220; PMCID: PMC3280805.
    77. Pope WB, Mirsadraei L, Lai A, Eskin A, Qiao J, Kim HJ, Ellingson B, Nghiemphu PL, Kharbanda S, Soriano RH, Nelson SF, Yong W, Phillips HS, Cloughesy TF. Differential gene expression in glioblastoma defined by ADC histogram analysis: relationship to extracellular matrix molecules and survival. AJNR Am J Neuroradiol. 2012 Jun; 33(6):1059-64. PMID: 22268080.
      View in: PubMed
    78. Norden AD, Pope WB, Chang SM. Current concepts in brain tumor imaging. Am Soc Clin Oncol Educ Book. 2012; 119-24. PMID: 24451720.
      View in: PubMed
    79. Schwarzenberg J, Czernin J, Cloughesy TF, Ellingson BM, Pope WB, Geist C, Dahlbom M, Silverman DH, Satyamurthy N, Phelps ME, Chen W. 3'-deoxy-3'-18F-fluorothymidine PET and MRI for early survival predictions in patients with recurrent malignant glioma treated with bevacizumab. J Nucl Med. 2012 Jan; 53(1):29-36. PMID: 22159180; PMCID: PMC3424269.
    80. Lai A, Kharbanda S, Pope WB, Tran A, Solis OE, Peale F, Forrest WF, Pujara K, Carrillo JA, Pandita A, Ellingson BM, Bowers CW, Soriano RH, Schmidt NO, Mohan S, Yong WH, Seshagiri S, Modrusan Z, Jiang Z, Aldape KD, Mischel PS, Liau LM, Escovedo CJ, Chen W, Nghiemphu PL, James CD, Prados MD, Westphal M, Lamszus K, Cloughesy T, Phillips HS. Evidence for sequenced molecular evolution of IDH1 mutant glioblastoma from a distinct cell of origin. J Clin Oncol. 2011 Dec 01; 29(34):4482-90. PMID: 22025148; PMCID: PMC3236649.
    81. Gomez C, Wu J, Pope W, Vinters H, Desalles A, Selch M. Pineocytoma with diffuse dissemination to the leptomeninges. Rare Tumors. 2011 Oct 21; 3(4):e53. PMID: 22355508; PMCID: PMC3282458.
    82. Pope WB, Prins RM, Albert Thomas M, Nagarajan R, Yen KE, Bittinger MA, Salamon N, Chou AP, Yong WH, Soto H, Wilson N, Driggers E, Jang HG, Su SM, Schenkein DP, Lai A, Cloughesy TF, Kornblum HI, Wu H, Fantin VR, Liau LM. Non-invasive detection of 2-hydroxyglutarate and other metabolites in IDH1 mutant glioma patients using magnetic resonance spectroscopy. J Neurooncol. 2012 Mar; 107(1):197-205. PMID: 22015945; PMCID: PMC3650613.
    83. Ellingson BM, Cloughesy TF, Pope WB, Zaw TM, Phillips H, Lalezari S, Nghiemphu PL, Ibrahim H, Naeini KM, Harris RJ, Lai A. Anatomic localization of O6-methylguanine DNA methyltransferase (MGMT) promoter methylated and unmethylated tumors: a radiographic study in 358 de novo human glioblastomas. Neuroimage. 2012 Jan 16; 59(2):908-16. PMID: 22001163.
      View in: PubMed
    84. Ellingson BM, Cloughesy TF, Lai A, Mischel PS, Nghiemphu PL, Lalezari S, Schmainda KM, Pope WB. Graded functional diffusion map-defined characteristics of apparent diffusion coefficients predict overall survival in recurrent glioblastoma treated with bevacizumab. Neuro Oncol. 2011 Oct; 13(10):1151-61. PMID: 21856685; PMCID: PMC3177656.
    85. Ellingson BM, Cloughesy TF, Lai A, Nghiemphu PL, Lalezari S, Zaw T, Motevalibashinaeini K, Mischel PS, Pope WB. Quantification of edema reduction using differential quantitative T2 (DQT2) relaxometry mapping in recurrent glioblastoma treated with bevacizumab. J Neurooncol. 2012 Jan; 106(1):111-9. PMID: 21706273.
      View in: PubMed
    86. Ellingson BM, Cloughesy TF, Lai A, Nghiemphu PL, Pope WB. Nonlinear registration of diffusion-weighted images improves clinical sensitivity of functional diffusion maps in recurrent glioblastoma treated with bevacizumab. Magn Reson Med. 2012 Jan; 67(1):237-45. PMID: 21702063.
      View in: PubMed
    87. Pope WB, Young JR, Ellingson BM. Advances in MRI assessment of gliomas and response to anti-VEGF therapy. Curr Neurol Neurosci Rep. 2011 Jun; 11(3):336-44. PMID: 21234719; PMCID: PMC3075404.
    88. Ellingson BM, Cloughesy TF, Lai A, Nghiemphu PL, Liau LM, Pope WB. High order diffusion tensor imaging in human glioblastoma. Acad Radiol. 2011 Aug; 18(8):947-54. PMID: 21536466.
      View in: PubMed
    89. Ellingson BM, Cloughesy TF, Lai A, Nghiemphu PL, Pope WB. Cell invasion, motility, and proliferation level estimate (CIMPLE) maps derived from serial diffusion MR images in recurrent glioblastoma treated with bevacizumab. J Neurooncol. 2011 Oct; 105(1):91-101. PMID: 21442275.
      View in: PubMed
    90. Pope WB, Lai A, Mehta R, Kim HJ, Qiao J, Young JR, Xue X, Goldin J, Brown MS, Nghiemphu PL, Tran A, Cloughesy TF. Apparent diffusion coefficient histogram analysis stratifies progression-free survival in newly diagnosed bevacizumab-treated glioblastoma. AJNR Am J Neuroradiol. 2011 May; 32(5):882-9. PMID: 21330401.
      View in: PubMed
    91. Ellingson BM, Cloughesy TF, Lai A, Nghiemphu PL, Mischel PS, Pope WB. Quantitative volumetric analysis of conventional MRI response in recurrent glioblastoma treated with bevacizumab. Neuro Oncol. 2011 Apr; 13(4):401-9. PMID: 21324937; PMCID: PMC3064698.
    92. Pope WB, Xia Q, Paton VE, Das A, Hambleton J, Kim HJ, Huo J, Brown MS, Goldin J, Cloughesy T. Patterns of progression in patients with recurrent glioblastoma treated with bevacizumab. Neurology. 2011 Feb 01; 76(5):432-7. PMID: 21282590.
      View in: PubMed
    93. Lai A, Tran A, Nghiemphu PL, Pope WB, Solis OE, Selch M, Filka E, Yong WH, Mischel PS, Liau LM, Phuphanich S, Black K, Peak S, Green RM, Spier CE, Kolevska T, Polikoff J, Fehrenbacher L, Elashoff R, Cloughesy T. Phase II study of bevacizumab plus temozolomide during and after radiation therapy for patients with newly diagnosed glioblastoma multiforme. J Clin Oncol. 2011 Jan 10; 29(2):142-8. PMID: 21135282; PMCID: PMC3058273.
    94. Wagle N, Nghiemphu L, Lai A, Pope W, Mischel PS, Cloughesy T. Update and developments in the treatment of glioblastoma multiforme - focus on bevacizumab. Pharmgenomics Pers Med. 2010; 3:79-85. PMID: 23226044; PMCID: PMC3513210.
    95. Ringman JM, Pope W, Salamon N. Insensitivity of visual assessment of hippocampal atrophy in familial Alzheimer's disease. J Neurol. 2010 May; 257(5):839-42. PMID: 20047059; PMCID: PMC2864895.
    96. Pope WB, Itagaki MW. Characterizing brain tumor research: the role of the National Institutes of Health. AJNR Am J Neuroradiol. 2010 Apr; 31(4):605-9. PMID: 20007725.
      View in: PubMed
    97. Kappadakunnel M, Eskin A, Dong J, Nelson SF, Mischel PS, Liau LM, Ngheimphu P, Lai A, Cloughesy TF, Goldin J, Pope WB. Stem cell associated gene expression in glioblastoma multiforme: relationship to survival and the subventricular zone. J Neurooncol. 2010 Feb; 96(3):359-67. PMID: 19655089; PMCID: PMC2808508.
    98. Pope WB, Kim HJ, Huo J, Alger J, Brown MS, Gjertson D, Sai V, Young JR, Tekchandani L, Cloughesy T, Mischel PS, Lai A, Nghiemphu P, Rahmanuddin S, Goldin J. Recurrent glioblastoma multiforme: ADC histogram analysis predicts response to bevacizumab treatment. Radiology. 2009 Jul; 252(1):182-9. PMID: 19561256.
      View in: PubMed
    99. Khanlou N, Mathern GW, Mitchell WG, Salamon N, Pope WB, Yong WH, Vinters HV. Cortical dysplasia with prominent Rosenthal fiber formation in a case of intractable pediatric epilepsy. Hum Pathol. 2009 Aug; 40(8):1200-4. PMID: 19427021.
      View in: PubMed
    100. Harley EM, Pope WB, Villablanca JP, Mumford J, Suh R, Mazziotta JC, Enzmann D, Engel SA. Engagement of fusiform cortex and disengagement of lateral occipital cortex in the acquisition of radiological expertise. Cereb Cortex. 2009 Nov; 19(11):2746-54. PMID: 19321653; PMCID: PMC2758686.
    101. Pope WB, Chen JH, Dong J, Carlson MR, Perlina A, Cloughesy TF, Liau LM, Mischel PS, Nghiemphu P, Lai A, Nelson SF. Relationship between gene expression and enhancement in glioblastoma multiforme: exploratory DNA microarray analysis. Radiology. 2008 Oct; 249(1):268-77. PMID: 18796682; PMCID: PMC2798090.
    102. Ledezma CJ, Chen W, Sai V, Freitas B, Cloughesy T, Czernin J, Pope W. 18F-FDOPA PET/MRI fusion in patients with primary/recurrent gliomas: initial experience. Eur J Radiol. 2009 Aug; 71(2):242-8. PMID: 18511228.
      View in: PubMed
    103. Nghiemphu PL, Green RM, Pope WB, Lai A, Cloughesy TF. Safety of anticoagulation use and bevacizumab in patients with glioma. Neuro Oncol. 2008 Jun; 10(3):355-60. PMID: 18436627; PMCID: PMC2563058.
    104. Ananthnarayan S, Bahng J, Roring J, Nghiemphu P, Lai A, Cloughesy T, Pope WB. Time course of imaging changes of GBM during extended bevacizumab treatment. J Neurooncol. 2008 Jul; 88(3):339-47. PMID: 18389177.
      View in: PubMed
    105. Lai A, Filka E, McGibbon B, Nghiemphu PL, Graham C, Yong WH, Mischel P, Liau LM, Bergsneider M, Pope W, Selch M, Cloughesy T. Phase II pilot study of bevacizumab in combination with temozolomide and regional radiation therapy for up-front treatment of patients with newly diagnosed glioblastoma multiforme: interim analysis of safety and tolerability. Int J Radiat Oncol Biol Phys. 2008 Aug 01; 71(5):1372-80. PMID: 18355978.
      View in: PubMed
    106. Morioka CA, El-Saden S, Pope W, Sayre J, Duckwiler G, Meng F, Bui A, Kangarloo H. A methodology to integrate clinical data for the efficient assessment of brain-tumor patients. Inform Health Soc Care. 2008 Mar; 33(1):55-68. PMID: 18604762.
      View in: PubMed
    107. Nael K, Villablanca JP, Mossaz L, Pope W, Juncosa A, Laub G, Finn JP. 3-T contrast-enhanced MR angiography in evaluation of suspected intracranial aneurysm: comparison with MDCT angiography. AJR Am J Roentgenol. 2008 Feb; 190(2):389-95. PMID: 18212224.
      View in: PubMed
    108. Chen W, Delaloye S, Silverman DH, Geist C, Czernin J, Sayre J, Satyamurthy N, Pope W, Lai A, Phelps ME, Cloughesy T. Predicting treatment response of malignant gliomas to bevacizumab and irinotecan by imaging proliferation with [18F] fluorothymidine positron emission tomography: a pilot study. J Clin Oncol. 2007 Oct 20; 25(30):4714-21. PMID: 17947718.
      View in: PubMed
    109. Carlson MR, Pope WB, Horvath S, Braunstein JG, Nghiemphu P, Tso CL, Mellinghoff I, Lai A, Liau LM, Mischel PS, Dong J, Nelson SF, Cloughesy TF. Relationship between survival and edema in malignant gliomas: role of vascular endothelial growth factor and neuronal pentraxin 2. Clin Cancer Res. 2007 May 01; 13(9):2592-8. PMID: 17473188.
      View in: PubMed
    110. Nael K, Villablanca JP, Pope WB, McNamara TO, Laub G, Finn JP. Supraaortic arteries: contrast-enhanced MR angiography at 3.0 T--highly accelerated parallel acquisition for improved spatial resolution over an extended field of view. Radiology. 2007 Feb; 242(2):600-9. PMID: 17255428.
      View in: PubMed
    111. Chen W, Silverman DH, Delaloye S, Czernin J, Kamdar N, Pope W, Satyamurthy N, Schiepers C, Cloughesy T. 18F-FDOPA PET imaging of brain tumors: comparison study with 18F-FDG PET and evaluation of diagnostic accuracy. J Nucl Med. 2006 Jun; 47(6):904-11. PMID: 16741298.
      View in: PubMed
    112. Pope WB, Lai A, Nghiemphu P, Mischel P, Cloughesy TF. MRI in patients with high-grade gliomas treated with bevacizumab and chemotherapy. Neurology. 2006 Apr 25; 66(8):1258-60. PMID: 16636248.
      View in: PubMed
    113. Nael K, Ruehm SG, Michaely HJ, Pope W, Laub G, Finn JP, Villablanca JP. High spatial-resolution CE-MRA of the carotid circulation with parallel imaging: comparison of image quality between 2 different acceleration factors at 3.0 Tesla. Invest Radiol. 2006 Apr; 41(4):391-9. PMID: 16523022.
      View in: PubMed
    114. Pope WB, Sayre J, Perlina A, Villablanca JP, Mischel PS, Cloughesy TF. MR imaging correlates of survival in patients with high-grade gliomas. AJNR Am J Neuroradiol. 2005 Nov-Dec; 26(10):2466-74. PMID: 16286386.
      View in: PubMed
    Whitney's Networks
    Concepts
    Derived automatically from this person's publications.
    _
    Co-Authors
    People in Profiles who have published with this person.
    _
    Related Authors
    People who share related concepts with this person.
    _